Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jean-Yves Douillard MD, PhD
Jean-Yves Douillard MD, PhD Advisory Board
Sara Tolaney MD, MPH
Sara M. Tolaney MD, MPH Advisory Board
Elizabeth Smyth MD
Elizabeth Smyth MD Advisory Board
See All Experts
featured
Published in Oncology

Expert Opinion / Conference Coverage · October 03, 2014

ESMO Interview: Lung Cancer Studies—Part 1

Jarushka Naidoo MD
Jean-Yves Douillard MD, PhD

 

 Save  Recommend
 Share

Additional Info

  1. Mok TSK, Wu Y, Nakagawa K, et al. Gefitinib/Chemotherapy vs Chemotherapy in Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small-Cell Lung Cancer (NSCLC) After Progression on First-Line Gefitinib: The Phase III Randomised IMPRESS Study. Ann Oncol. 2014;25(Suppl 4). Abstract LBA2_PR.
  2. Vansteenkiste JF, Cho B, Vanakesa T, et al. MAGRIT, a Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of the RECMAGE-A3 + AS15 Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected MAGE-A3-Positive Non-Small Cell Lung Cancer (NSCLC). Ann Oncol. 2014;25(Suppl 4):iv409.
  3. Park K, Ahn M-J, Yu C-J, et al. ASPIRATION: first-line erlotinib (E) until and beyond RECIST progression (PD) in Asian patients (pts) with EGFR mutation-positive (mut+) NSCLC. Ann Oncol. 2014;25(Suppl 4):iv426-iv427.

Further Reading

Most Read This Week

Recently Updated